Context Therapeutics Inc. business relationships
Companies named in Context Therapeutics Inc.’s 10-K filed 2026-03-23, and public companies whose annual reports name Context Therapeutics Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 18 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Context Therapeutics Inc.’s annual report 4
“On September 23, 2024, we entered into a license agreement (the "BioAtla License Agreement") with BioAtla, Inc. ("BioAtla"), pursuant to which we obtained an exclusive, worldwide license to develop, manufacture and commercialize two licensed antibodies (the "BioAtla Assets"), including BA3362 (renam...” SEC filing
“The Company has obtained active pharmaceutical ingredients and drug product for its product candidates from several third-party contract manufacturers, including Lonza Sales AG ("Lonza Sales") and Lonza AG ("Lonza AG", and collectively with Lonza Sales, "Lonza").” SEC filing
“As of March 1, 2026, the Integral Molecular, Inc. patent portfolio covering CTIM-76 and methods of use that we exclusively licensed pursuant to the Integral License Agreement includes three granted U.S. patents, two pending U.S. non-provisional applications, granted patents in China, Eurasia, Japan,...” SEC filing
“In April 2021, we entered into a collaboration and licensing agreement with Integral Molecular, Inc. ("Integral") (the "Integral License Agreement") for the development of a CLDN6 bsAb for cancer therapy.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.